The Role of Gut Microbiota in Metabolic Dysfunction-Associated Fatty Liver Disease (MASLD) DOI Creative Commons
Săndica Bucurică

IntechOpen eBooks, Journal Year: 2024, Volume and Issue: unknown

Published: Dec. 13, 2024

Gut microbiota plays a critical role in developing and progressing metabolic dysfunction-associated steatotic liver disease (MASLD). Studies show reduced microbial diversity specific shifts bacterial populations MASLD patients, with harmful species increasing beneficial ones decreasing. These changes contribute to fat accumulation by impairing fiber fermentation, disrupting bile acid metabolism, intestinal permeability, promoting inflammation. The progression of is linked evolving changes, probiotics like Lactobacillus plantarum potential mitigating restoring gut balance. Thus, serves as both key factor therapeutic target MASLD. Interventions on are possible targets treating or preventing toward advanced stages. At the same time, prebiotics have shown results ameliorating MASLD, post-biotic therapy, immuno-nutrition, bacteria engineering, phages, which been applied only experimental studies.

Language: Английский

Targeting Metabolic Diseases: The Role of Nutraceuticals in Modulating Oxidative Stress and Inflammation DOI Open Access

Aida Dama,

Kleva Shpati, Patricia Daliu

et al.

Nutrients, Journal Year: 2024, Volume and Issue: 16(4), P. 507 - 507

Published: Feb. 10, 2024

The escalating prevalence of metabolic and cardiometabolic disorders, often characterized by oxidative stress chronic inflammation, poses significant health challenges globally. As the traditional therapeutic approaches may sometimes fall short in managing these conditions, attention is growing toward nutraceuticals worldwide; with compounds being obtained from natural sources potential beneficial effects shown to potentially support and, some cases, replace pharmacological treatments, especially for individuals who do not qualify conventional treatments. This review delves into burgeoning field nutraceutical-based modulation as a promising strategy attenuating inflammation disorders. Drawing an extensive body research, showcases various nutraceutical agents, such polyphenols, omega-3 fatty acids, antioxidants, which exhibit antioxidative anti-inflammatory properties. All can be classified novel drugs that are capable regulating pathways mitigate oxidative-stress- inflammation-associated diseases. By exploring mechanisms through interact immune responses, this highlights their restore redox balance temper inflammation. Additionally, prospects interventions discussed, encompassing bioavailability enhancement, personalized treatment approaches, clinical translation. Through comprehensive analysis latest scientific reports, article underscores avenue fight complex landscape particularly accentuating impact on cardiovascular health.

Language: Английский

Citations

36
The Asian Pacific association for the study of the liver clinical practice guidelines for the diagnosis and management of metabolic dysfunction-associated fatty liver disease DOI Creative Commons
Mohammed Eslam, Jian‐Gao Fan, Ming‐Lung Yu

et al.

Hepatology International, Journal Year: 2025, Volume and Issue: unknown

Published: Feb. 27, 2025

Language: Английский

Citations

4
Endothelial Dysfunction: Redox Imbalance, NLRP3 Inflammasome, and Inflammatory Responses in Cardiovascular Diseases DOI Creative Commons
Cláudia Penna, Pasquale Pagliaro

Antioxidants, Journal Year: 2025, Volume and Issue: 14(3), P. 256 - 256

Published: Feb. 23, 2025

Endothelial dysfunction (ED) is characterized by an imbalance between vasodilatory and vasoconstrictive factors, leading to impaired vascular tone, thrombosis, inflammation. These processes are critical in the development of cardiovascular diseases (CVDs) such as atherosclerosis, hypertension ischemia/reperfusion injury (IRI). Reduced nitric oxide (NO) production increased oxidative stress key contributors ED. Aging further exacerbates ED through mitochondrial oxidative/nitrosative stress, heightening CVD risk. Antioxidant systems like superoxide-dismutase (SOD), glutathione-peroxidase (GPx), thioredoxin/thioredoxin-reductase (Trx/TXNRD) pathways protect against stress. However, their reduced activity promotes ED, vulnerability IRI. Metabolic syndrome, comprising insulin resistance, obesity, hypertension, often accompanied Specifically, hyperglycemia worsens endothelial damage promoting Obesity leads chronic inflammation changes perivascular adipose tissue, while associated with increase The NLRP3 inflammasome plays a significant role being triggered factors reactive oxygen nitrogen species, ischemia, high glucose, which contribute inflammation, injury, exacerbation Treatments, N-acetyl-L-cysteine, SGLT2 or inhibitors, show promise improving function. Yet complexity suggests that multi-targeted therapies addressing metabolic disturbances essential for managing CVDs syndrome.

Language: Английский

Citations

2
MAFLD as part of systemic metabolic dysregulation DOI
Jing Zhao, Lu Liu,

Yingying Cao

et al.

Hepatology International, Journal Year: 2024, Volume and Issue: 18(S2), P. 834 - 847

Published: April 9, 2024

Language: Английский

Citations

15
Altered Mitochondrial Function in MASLD: Key Features and Promising Therapeutic Approaches DOI Creative Commons
Tatjana Radosavljević,

Milica Branković,

Janko Samardžić

et al.

Antioxidants, Journal Year: 2024, Volume and Issue: 13(8), P. 906 - 906

Published: July 26, 2024

Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as nonalcoholic fatty (NAFLD), encompasses a range of conditions from steatosis to steatohepatitis (NASH). Its prevalence, especially among patients with metabolic syndrome, highlights its growing global impact. The pathogenesis MASLD involves dysregulation, inflammation, oxidative stress, genetic factors and, notably, mitochondrial dysfunction. Recent studies underscore the critical role dysfunction in MASLD's progression. Therapeutically, enhancing function has gained interest, along lifestyle changes and pharmacological interventions targeting processes. FDA's approval resmetirom for metabolic-associated (MASH) fibrosis marks significant step. While represents progress, further research is essential understand MASLD-related fully. Innovative strategies like gene editing small-molecule modulators, alongside interventions, can potentially improve treatment. Drug repurposing new targets will advance therapy, addressing increasing burden. Therefore, this review aims provide better understanding identify more effective preventive treatment strategies.

Language: Английский

Citations

12
Metabolic dysfunction-associated steatotic liver disease and cardiovascular risk: a comprehensive review DOI Creative Commons

Haixiang Zheng,

Leonardo A. Sechi, Eliano Pio Navarese

et al.

Cardiovascular Diabetology, Journal Year: 2024, Volume and Issue: 23(1)

Published: Sept. 28, 2024

Language: Английский

Citations

12
Identification of EGR1 as a Key Diagnostic Biomarker in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) Through Machine Learning and Immune Analysis DOI Creative Commons

Xuanlin Wu,

Tao Pan, Zhihao Fang

et al.

Journal of Inflammation Research, Journal Year: 2025, Volume and Issue: Volume 18, P. 1639 - 1656

Published: Feb. 1, 2025

Background: Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), as a common chronic liver condition globally, is experiencing an increasing incidence rate which poses significant health risks. Despite this, the detailed mechanisms underlying disease's onset and progression remain poorly understood. In this study, we aim to identify effective diagnostic biomarkers for MASLD using microarray data combined with machine learning techniques, will aid in further understanding pathogenesis of MASLD. Methods: We collected six datasets from Gene Expression Omnibus (GEO) database, five them training sets one validation set. employed three methods—LASSO, SVM, Random Forest (RF)—to hub genes associated These were validated external dataset GSE164760. Additionally, functional enrichment analysis, immune infiltration function analysis conducted. A TF-miRNA-mRNA network was constructed, single-cell RNA sequencing used determine distribution key within cell clusters. Finally, expression palmitic acid-induced AML-12 line MCD mouse model. Results: through differential gene (DEGs) successfully identified 10 genes. Among these, EGR1 screened dataset, area under curve (AUC) 0.882. Enrichment analyses assessments revealed multiple pathways involving MASLD, showing correlations various cells. Furthermore, additional cellular experiments animal model validations confirmed that trends are highly consistent our analytical findings. Conclusion: Our research has providing novel insights into identifying new therapeutic targets its treatment. Keywords: metabolic dysfunction-associated steatotic disease, infiltration, learning, network,

Language: Английский

Citations

1
Transforming Screening, Risk Stratification, and Treatment Optimization in Chronic Liver Disease Through Data Science and translational Innovation DOI Creative Commons

Tamer A. Addissouky

The Indonesian Journal of Gastroenterology Hepatology and Digestive Endoscopy, Journal Year: 2024, Volume and Issue: 25(1), P. 53 - 62

Published: May 16, 2024

Background: Chronic liver diseases continue to face challenges in prognosis, treatment selection, disease mechanisms, screening, and therapeutic optimization. Promising innovations could address these gaps through data integration novel analytic approaches.Main Body: MAPS-CRAFITY integrating clinical variables, AFP, CT/MRI findings, transformer modeling of RFA improve HCC outcome prediction guide management. Analyses revealing IL21R as a PBC susceptibility gene implicating dysfunctional VWF processing portal hypertension deliver mechanistic insights. Quantifying childhood MAFLD informs screening needs, while supporting use G6PD deficient donors enables transplantation access expansion risk stratification. Updating Baveno criteria enhances an prognostic score identifies optimal candidates maximize efficacy.Conclusion: Recent research leverages diverse types, genetics, imaging, machine learning develop integrated predictive systems that allow more personalized therapy selection. Elucidating molecular pathways provides targets biomarkers. Evidence-based models facilitate delivering tailored interventions. Optimization current modalities validation patient selection improves real-world effectiveness. Multifaceted modern approaches promise unmet needs transform hepatology care.

Language: Английский

Citations

6
The multiple mechanisms and therapeutic significance of rutin in metabolic dysfunction-associated fatty liver disease (MAFLD) DOI

Qianzhuo Wang,

Yingjuan Zhang,

Ruiling Lu

et al.

Fitoterapia, Journal Year: 2024, Volume and Issue: 178, P. 106178 - 106178

Published: Aug. 15, 2024

Language: Английский

Citations

6
Excess cardiovascular mortality in men with non-alcoholic fatty liver disease: A cause for concern! DOI Open Access
Akash Batta, Juniali Hatwal

World Journal of Cardiology, Journal Year: 2024, Volume and Issue: 16(7), P. 380 - 384

Published: July 24, 2024

Non-alcoholic fatty liver disease (NAFLD) has emerged as the commonest cause of chronic worldwide in recent years. With time, our understanding NAFLD evolved from an isolated condition to a systemic with significant manifestations beyond liver. Amongst them, cardiovascular diseases (CVDs) are most important and clinically relevant. Recent research supports strong independent link between NALFD CVD shared risk factors pathophysiology. Female sex hormones well known not only protect against pre-menopausal females, but also contribute improved adipose tissue function preventing its deposition. highlights increased major adverse cardiovascular-cerebral events (MACCE) amongst male compared females. Further, racial variation was observed MACCE outcomes NAFLD, excess mortality Native Americans Asian Pacific Islanders other races.

Language: Английский

Citations

5